dc.contributor.author | Andersen, Jintana Bunpan | en_US |
dc.contributor.author | Owe, Jone Furulund | en_US |
dc.contributor.author | Engeland, Anders | en_US |
dc.contributor.author | Gilhus, Nils Erik | en_US |
dc.date.accessioned | 2014-12-03T13:17:58Z | |
dc.date.available | 2014-12-03T13:17:58Z | |
dc.date.issued | 2014-04-09 | eng |
dc.identifier.issn | 1351-5101 | |
dc.identifier.uri | https://hdl.handle.net/1956/8819 | |
dc.description.abstract | Background and purpose: Comorbidity in myasthenia gravis (MG) is important for diagnosis, treatment and prognosis. Disease complexity was assessed by examining total drug treatment, immune therapy and comorbidity in a complete national MG cohort. Methods: All recipients of the MG-specific drug pyridostigmine 2004–2010 registered in the compulsory Norwegian Prescription Database who met the inclusion criteria were included. The pyridostigmine group was compared with the general Norwegian population. Results: Myasthenia gravis patients received co-medication more often than the controls for nearly all groups of medication, including insulins (95% confidence interval 2.0–3.7), thyroid therapy (1.7–2.5), antidepressants (1.3–1.7), anti-infectives (1.2–1.4), lipid-modifying agents (1.1–1.4) and immunomodulating agents (6.8–8.8). Conclusions: Myasthenia gravis patients are more often treated with non-MG prescription drugs than controls, reflecting frequent co-medication and comorbidity. | en_US |
dc.language.iso | eng | eng |
dc.publisher | Wiley | eng |
dc.relation.ispartof | <a href="http://hdl.handle.net/1956/11708" target="blank">Epidemiology, comorbidity and clinical course of myasthenia gravis. A registry-based study</a> | eng |
dc.rights | Attribution-NonCommercial-NoDerivs CC BY-NC-ND | eng |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | eng |
dc.subject | Co-morbidity | eng |
dc.subject | Drug therapy | eng |
dc.subject | myasthenia gravis | eng |
dc.title | Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study | en_US |
dc.type | Peer reviewed | |
dc.type | Journal article | |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2014 The Author(s) | |
dc.identifier.doi | https://doi.org/10.1111/ene.12439 | |
dc.identifier.cristin | 1163664 | |
dc.source.journal | European Journal of Neurology | |
dc.source.40 | 21 | |
dc.source.14 | 7 | |
dc.source.pagenumber | 948-955 | |